Efficacy Safety and Immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in Neonates

  • End date
    Jan 29, 2023
  • participants needed
  • sponsor
    PT Bio Farma
Updated on 29 August 2021


This phase III trial aims to assess the efficacy, safety and immunogenicity of Rotavirus RV3 Vaccine (Bio Farma) in neonates, lot-to-lot consistency, and antigen interference with co-administered EPI vaccines


This study is a randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and immunogenicity following three doses of rotavirus RV3 vaccine (Bio Farma) administered as a neonatal schedule

Condition Rotavirus Gastroenteritis
Treatment Placebo, Rotavirus RV3 Vaccine (Bio Farma)
Clinical Study IdentifierNCT04185545
SponsorPT Bio Farma
Last Modified on29 August 2021


Yes No Not Sure

Inclusion Criteria

Neonate 0-5 days (0-144 hours) of age at the time of first dose
Neonate is in good health as determined by clinical judgment, including a medical history and physical exam, which confirms the absence of a current or past disease state considered significant by the investigator
The neonate was born full term (minimum of 37 completed weeks and maximum of 42 completed weeks gestation)
Neonate birth weight 2500-4000 g inclusive
Parent or guardian has been informed properly regarding the study and signed the informed consent form
Parent or guardian commits to comply with the instructions of the investigator and the schedule of the trial

Exclusion Criteria

Subject concomitantly enrolled or scheduled to be enrolled in another trial
The subject has direct relatives relationship with the study team
The subject has evolving mild, moderate or severe illness, especially infectious diseases or fever (body temperature 37.5C) within the 48 hours preceding enrollment
Subject with a known or suspected history of allergy to any component of the vaccines (based on anamnesis)
Subject with a biological mother with a known or suspected human immunodeficiency virus (HIV) or Hepatitis B infection
Subject with known or suspected major congenital malformations or genetically determined disease
Subject with intussusception
Subject with a known or suspected disease of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy
Subject with a known or suspected disease of the immune system or those who have received immunosuppressive therapy, including immunosuppressive courses of systemic corticosteroid
Subject who have ever received any blood products, including immunoglobulin, or for whom receipt of any blood product is anticipated during the course of study
Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives
Subject immunized with non-EPI vaccines
Gastroenteritis in the 24 hours preceding dosing (temporary exclusion criteria)
Subject planning to move from the study area before the end of the study period
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note